Dipasic on the resistance of Mycobacterium tuberculosis.docVIP

 PAGE \* MERGEFORMAT 14 Dipasic on the resistance of Mycobacterium tuberculosis 【Abstract】: Objective: To understand the Dipasic on the validity of its drug resistant strains inhibitory concentration. Methods: Susceptibility to add 10 different medium concentrations of anti-TB drugs, by adding TB bacilli 10-3 mg. Results: After 4 weeks of observation of three kinds of anti-TB drug resistance. Conclusions: DPC is an independent anti-TB drugs are effective against drug-resistant tuberculosis, but there are still 30% when the concentration of 1μg growth, that the amount of dosage should be doubled. Keywords:: Dipasic resistance 【Papers】: the use of anti-tuberculosis drugs in tuberculosis prevention and control played a landmark role. 50 years combined treatment with INH PAS has achieved better effect. However, taking large amount of PAS, gastrointestinal reactions and more patients can not tolerate, 90% could not complete the treatment process. The Swiss pharmaceutical Geistlich developed Dipasic (referred to as DPC) (Germany, also known as GEWO399), is a special method, INH and PAS synthetic compounds. It can replace the combination therapy INH PAS, increase efficacy, side effects significantly less than the PAS, Germany, Freudenthal, etc. more than 50 experts from both the clinical application of Dipasic report considered valid. But no Dipasic resistance reported. At present, China’s ever-increasing drug resistance of patients to seek rational use of medicines, is a priority, for which we have to make patience Dipasic purpose of the study is (1) Understanding the Dipasic pairs of drug-resistant strains effective? (2) Dipasic how the drug inhibitory concentration? Order to study the dosage and usage, to improve clinical efficacy. A research method: From the Anhui Medical University Affiliated Hospital out-patient clinics and ward for tuberculosis patients sputum TB culture, whether the patient is untreated retreatment suppression, nor s